Calcineurin Inhibitor Pharmacology
Deep dive into cyclosporine and tacrolimus -- binding partners, calcineurin-NFAT inhibition, pharmacokinetics, nephrotoxicity, and drug interactions.
## Mechanism of Action
Calcineurin inhibitors (CNIs) are the most widely used immunosuppressants in solid organ transplantation. **Cyclosporine** binds cyclophilin, and **tacrolimus** binds FKBP12. Both drug-immunophilin complexes inhibit calcineurin, a serine/threonine phosphatase that dephosphorylates NFAT (nuclear factor of activated T cells). Without dephosphorylation, NFAT cannot translocate to the nucleus, and transcription of IL-2 and other T-cell activation genes is blocked.
Tacrolimus is 10-100 times more potent than cyclosporine on a weight basis, and it has largely replaced cyclosporine in most transplant centers.
## Pharmacokinetics
Both CNIs have narrow therapeutic indices requiring therapeutic drug monitoring (TDM). Tacrolimus trough levels (C0) are targeted at 5-15 ng/mL depending on time post-transplant and organ type. Cyclosporine uses C0 or C2 (2-hour post-dose) monitoring.
Key pharmacokinetic properties:
- **Absorption**: Variable oral bioavailability (tacrolimus ~25%, cyclosporine ~30%). Food and bile salts affect absorption
- **Metabolism**: Both are CYP3A4 and P-glycoprotein substrates, creating extensive drug interaction potential
- **Distribution**: Highly protein-bound; tacrolimus binds primarily to erythrocytes and albumin
- **Elimination**: Hepatic metabolism; minimal renal excretion of parent compound
## Drug Interactions
CYP3A4 and P-gp interactions dominate CNI pharmacology. Strong CYP3A4 inhibitors (ketoconazole, erythromycin, grapefruit juice) dramatically increase CNI levels. Inducers (rifampin, phenytoin, St. John's wort) cause subtherapeutic levels and rejection risk.
Tacrolimus-azole antifungal co-administration may require 50-75% dose reductions. Conversely, rifampin co-administration may require 3-5x dose increases.
## Adverse Effects
**Nephrotoxicity** is the most significant CNI adverse effect, occurring via afferent arteriolar vasoconstriction (acute) and chronic tubulointerstitial fibrosis. Paradoxically, the drugs that prevent graft rejection also damage the transplanted kidney over time.
Other effects include neurotoxicity (tremor, headache, posterior reversible encephalopathy), hypertension, hyperglycemia (especially tacrolimus), dyslipidemia (especially cyclosporine), and gingival hyperplasia (cyclosporine). CNIs increase risk for opportunistic infections and certain malignancies (skin cancer, PTLD) due to sustained immunosuppression.
## Key Takeaways
- CNIs block calcineurin-NFAT signaling to suppress IL-2 production and T-cell activation
- Narrow therapeutic index mandates routine TDM (tacrolimus C0 target 5-15 ng/mL)
- CYP3A4/P-gp drug interactions require vigilant dose adjustments
- Chronic nephrotoxicity limits long-term use and drives search for CNI-free regimens